Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies
about
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancerThe role of tumor microenvironment in therapeutic resistanceOvine pulmonary adenocarcinoma: a large animal model for human lung cancerMulti-target drugs: the trend of drug research and developmentRegistered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulationsIn Silico Screening of Mutated K-Ras Inhibitors from Malaysian Typhonium flagelliforme for Non-Small Cell Lung Cancer.P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.A non-tight junction function of claudin-7-Interaction with integrin signaling in suppressing lung cancer cell proliferation and detachment.Personalized targeted therapy for lung cancerDetection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients.In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.WW45, a Gli1 binding protein, negatively regulated Hedgehog signaling in lung cancer.Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies.Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.New strategies to develop new medications for lung cancer and metastasis.Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells.Oncogenic driver mutations in lung cancer.Cytotoxic enhancement of hexapeptide-conjugated micelles in EGFR high-expressed cancer cells.Network understanding of herb medicine via rapid identification of ingredient-target interactions.Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells.[Epidermal growth factor receptor mutations and radiotherapy in non-small cell lung cancer].Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population.Loss of CDH1 up-regulates epidermal growth factor receptor via phosphorylation of YBX1 in non-small cell lung cancer cells.EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells.Upregulation of SALL4 by EGFR activation regulates the stemness of CD44-positive lung cancer.[EGFR-dependent impact of indol-3-carbinol on radiosensitivity of lung cancer cells].
P2860
Q24324198-24050CCA-41C6-4CCE-86EE-1AA981C53612Q28069049-4C6044F7-1D6F-4E2B-9E20-2EB46259E2C8Q28088774-5BAB7E83-FFD0-4B13-8C17-3F91926B906EQ28480888-BFDA6172-9E98-4DCB-A7B6-0BBC471BB845Q28603408-847D8E18-8EEE-4E0C-BD13-9630E69A60F1Q34305736-F051B423-C87C-4A6F-988A-DBEA7DC0F2BBQ34897198-5606BAB7-0BA3-4B5C-A599-FF9127750533Q35689752-E80EFE4A-92CD-4F4E-A5CF-0675B8FB2FD5Q35750069-05E2B7A6-2C3D-4848-814E-A2A805D0D7B5Q36321826-9C43130C-D3ED-4757-872B-4EC847CA4170Q36835257-098EF774-BB47-4046-9E68-39A855E2D509Q37418236-C57919D6-9481-4814-B7D7-9B89FE3C5F28Q37708883-E210EB2B-CEEA-4858-9FDD-FB2A454E6E0CQ38168795-E8C93808-77DC-4C58-AE22-76342E6C9C80Q38390205-4CDC31F5-7ECA-46D3-B49B-329283E09916Q38461521-268566AF-B5BB-4404-9DCA-66AA82C06738Q38807257-69B708D8-74D1-4EC0-9555-C57B2015C0F6Q38846405-FCFE07F4-20B1-49E8-BEEC-769FAAEB1456Q38982625-718C3739-6D03-478F-B0EF-C07817EEBA37Q39034124-94FAF1C7-FB47-4067-9A49-2C382C9968D4Q39129968-30D9F9D6-2BC8-4115-BF78-6B3ED40EF1FEQ44478432-0C14063C-3A64-4F09-80AA-967994B2D179Q49216496-FADBA574-A6FC-40E0-8910-1A38C39D9533Q50710542-6B036333-1896-407B-B98D-183C35272676Q51019075-FBFA05B7-E156-4B4D-A457-588F602295E5Q52565512-C0E64F4A-05C0-41DB-8283-356ED8835111Q54496147-6A88BFE7-3A4A-485E-B45B-EE8D29560477
P2860
Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies
@ast
Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies
@en
Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies
@nl
type
label
Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies
@ast
Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies
@en
Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies
@nl
prefLabel
Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies
@ast
Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies
@en
Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies
@nl
P2093
P1433
P1476
Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies
@en
P2093
Ernesto Pozzi
Francesca Cemmi
Giulia M. Stella
Maurizio Luisetti
Roberta Scabini
P304
P356
10.1016/J.RMED.2011.10.015
P407
P577
2012-02-01T00:00:00Z